Home›Trial›NCT06223958
🔬NCT06223958Phase 3ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Study Summary

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration

Conditions
Neovascular Age-Related Macular Degeneration
Interventions / Drugs
OTX-TKI (axitinib implant)Aflibercept
View on ClinicalTrials.gov ↗
Sponsor
OCUL
Ocular Therapeutix
Ophthalmology
D37/100
Study Details
Enrollment344 participants
Primary Completion—
Lead SponsorOcular Therapeutix, Inc.
Data Retrieved2026-04-11 04:23:15.556961+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.